Literature DB >> 20406959

Increased risk for lymphoid and myeloid neoplasms in elderly solid-organ transplant recipients.

Scott C Quinlan1, Lindsay M Morton, Ruth M Pfeiffer, Lesley A Anderson, Ola Landgren, Joan L Warren, Eric A Engels.   

Abstract

BACKGROUND: By assessing the spectrum of hematologic malignancies associated with solid-organ transplantation in the elderly, we provide information on the pathogenesis of lymphoid and myeloid neoplasms and the clinical manifestations of immunosuppression.
METHODS: Using data from the U.S. Surveillance, Epidemiology, and End Results Medicare database, we identified 83,016 cases with a hematologic malignancy (age 66-99 years) and 166,057 population-based controls matched to cases by age, sex, and calendar year. Medicare claims were used to identify a history of solid-organ transplantation. We used polytomous logistic regression to calculate odds ratios (OR) comparing transplantation history among cases with various hematologic malignancy subtypes and controls, adjusting for the matching factors and race.
RESULTS: A prior solid-organ transplant was identified in 216 (0.26%) cases and 204 (0.12%) controls. Transplantation was associated with increased risk for non-Hodgkin lymphomas [OR, 2.13; 95% confidence interval (95% CI), 1.67-2.72], especially diffuse large B-cell lymphoma (OR, 3.29; 95% CI, 2.28-4.76), marginal zone lymphoma (OR, 2.48; 95% CI, 1.17-5.22), lymphoplasmacytic lymphoma (OR, 3.32; 95% CI, 1.41-7.81), and T-cell lymphoma (OR, 3.07; 95% CI, 1.56-6.06). Transplantation was also associated with elevated risk of Hodgkin lymphoma (OR, 2.53; 95% CI, 1.01-6.35) and plasma cell neoplasms (OR, 1.91; 95% CI, 1.24-2.93). Risks for myeloid neoplasms were also elevated (OR, 1.99; 95% CI, 1.41-2.81).
CONCLUSION: Solid-organ transplantation is associated with a wide spectrum of hematologic malignancies in the elderly. Risk was increased for four specific non-Hodgkin lymphoma subtypes for which a viral agent has been implicated, supporting an added role for immunosuppression. IMPACT: Our results support monitoring for a wide spectrum of hematologic malignancies following solid-organ transplant. Copyright (c) 2010 AACR

Entities:  

Mesh:

Year:  2010        PMID: 20406959      PMCID: PMC2866098          DOI: 10.1158/1055-9965.EPI-09-1220

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  37 in total

1.  Trends in organ donation and transplantation in the United States, 1997-2006.

Authors:  F K Port; R M Merion; E C Roys; R A Wolfe
Journal:  Am J Transplant       Date:  2008-04       Impact factor: 8.086

2.  Lymphoproliferative disease after renal transplantation in Australia and New Zealand.

Authors:  Randall J Faull; Peter Hollett; Stephen P McDonald
Journal:  Transplantation       Date:  2005-07-27       Impact factor: 4.939

3.  Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph).

Authors:  Lindsay M Morton; Jennifer J Turner; James R Cerhan; Martha S Linet; Patrick A Treseler; Christina A Clarke; Andrew Jack; Wendy Cozen; Marc Maynadié; John J Spinelli; Adele Seniori Costantini; Thomas Rüdiger; Aldo Scarpa; Tongzhang Zheng; Dennis D Weisenburger
Journal:  Blood       Date:  2007-03-27       Impact factor: 22.113

Review 4.  Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation.

Authors:  Anna L Taylor; Robert Marcus; J Andrew Bradley
Journal:  Crit Rev Oncol Hematol       Date:  2005-10       Impact factor: 6.312

5.  Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern Europe.

Authors:  Diego Serraino; Pierluca Piselli; Ghil Busnach; Patrizia Burra; Franco Citterio; Eloisa Arbustini; Umberto Baccarani; Emanuela De Juli; Ubaldo Pozzetto; Stefania Bellelli; Jerry Polesel; Christian Pradier; Luigino Dal Maso; Claudio Angeletti; Maria Patrizia Carrieri; Giovanni Rezza; Silvia Franceschi
Journal:  Eur J Cancer       Date:  2007-08-30       Impact factor: 9.162

6.  Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium.

Authors:  Silvia de Sanjose; Yolanda Benavente; Claire M Vajdic; Eric A Engels; Lindsay M Morton; Paige M Bracci; John J Spinelli; Tongzhang Zheng; Yawei Zhang; Silvia Franceschi; Renato Talamini; Elizabeth A Holly; Andrew E Grulich; James R Cerhan; Patricia Hartge; Wendy Cozen; Paolo Boffetta; Paul Brennan; Marc Maynadié; Pierluigi Cocco; Ramon Bosch; Lenka Foretova; Anthony Staines; Nikolaus Becker; Alexandra Nieters
Journal:  Clin Gastroenterol Hepatol       Date:  2008-04       Impact factor: 11.382

7.  Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus.

Authors:  Thomas P Giordano; Louise Henderson; Ola Landgren; Elizabeth Y Chiao; Jennifer R Kramer; Hashem El-Serag; Eric A Engels
Journal:  JAMA       Date:  2007-05-09       Impact factor: 56.272

8.  Hepatitis C virus infection and risk of posttransplantation lymphoproliferative disorder among solid organ transplant recipients.

Authors:  Lindsay M Morton; Ola Landgren; Nilanjan Chatterjee; David Castenson; Ruth Parsons; Robert N Hoover; Eric A Engels
Journal:  Blood       Date:  2007-09-12       Impact factor: 22.113

9.  AIDS-related cancer and severity of immunosuppression in persons with AIDS.

Authors:  Robert J Biggar; Anil K Chaturvedi; James J Goedert; Eric A Engels
Journal:  J Natl Cancer Inst       Date:  2007-06-12       Impact factor: 13.506

Review 10.  Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis.

Authors:  Andrew E Grulich; Marina T van Leeuwen; Michael O Falster; Claire M Vajdic
Journal:  Lancet       Date:  2007-07-07       Impact factor: 79.321

View more
  20 in total

Review 1.  Epidemiology of MPN: what do we know?

Authors:  L A Anderson; M F McMullin
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

2.  Hodgkin lymphoma post-transplant lymphoproliferative disorder: A comparative analysis of clinical characteristics, prognosis, and survival.

Authors:  Aaron S Rosenberg; Andreas K Klein; Robin Ruthazer; Andrew M Evens
Journal:  Am J Hematol       Date:  2016-04-26       Impact factor: 10.047

3.  Body mass index and physical activity at different ages and risk of multiple myeloma in the NIH-AARP diet and health study.

Authors:  Jonathan N Hofmann; Steven C Moore; Unhee Lim; Yikyung Park; Dalsu Baris; Albert R Hollenbeck; Charles E Matthews; Todd M Gibson; Patricia Hartge; Mark P Purdue
Journal:  Am J Epidemiol       Date:  2013-03-29       Impact factor: 4.897

4.  Use of surveillance, epidemiology, and end results-medicare data to conduct case-control studies of cancer among the US elderly.

Authors:  Eric A Engels; Ruth M Pfeiffer; Winnie Ricker; William Wheeler; Ruth Parsons; Joan L Warren
Journal:  Am J Epidemiol       Date:  2011-08-04       Impact factor: 4.897

5.  Survival Analyses and Prognosis of Plasma-Cell Myeloma and Plasmacytoma-Like Posttransplantation Lymphoproliferative Disorders.

Authors:  Aaron S Rosenberg; Robin Ruthazer; Jessica K Paulus; David M Kent; Andrew M Evens; Andreas K Klein
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-09-17

6.  Donor biomarkers as predictors of organ use and recipient survival after neurologically deceased donor organ transplantation.

Authors:  Shengnan Li; Shu Wang; Raghavan Murugan; Ali Al-Khafaji; Daniel J Lebovitz; Michael Souter; Susan R N Stuart; John A Kellum
Journal:  J Crit Care       Date:  2018-08-18       Impact factor: 3.425

7.  Hepatitis B virus infection and risk of lymphoma: results of a serological analysis within the European case-control study Epilymph.

Authors:  Nikolaus Becker; Paul Schnitzler; Paolo Boffetta; Paul Brennan; Lenka Foretova; Marc Maynadié; Alexandra Nieters; Anthony Staines; Yolanda Benavente; Pierluigi Cocco; Silvia de Sanjose
Journal:  J Cancer Res Clin Oncol       Date:  2012-07-06       Impact factor: 4.553

8.  Blood transfusions and the subsequent risk of hematologic malignancies.

Authors:  Cindy M Chang; Scott C Quinlan; Joan L Warren; Eric A Engels
Journal:  Transfusion       Date:  2010-10-04       Impact factor: 3.157

9.  Rationale and Design of the International Lymphoma Epidemiology Consortium (InterLymph) Non-Hodgkin Lymphoma Subtypes Project.

Authors:  Lindsay M Morton; Joshua N Sampson; James R Cerhan; Jennifer J Turner; Claire M Vajdic; Sophia S Wang; Karin E Smedby; Silvia de Sanjosé; Alain Monnereau; Yolanda Benavente; Paige M Bracci; Brian C H Chiu; Christine F Skibola; Yawei Zhang; Sam M Mbulaiteye; Michael Spriggs; Dennis Robinson; Aaron D Norman; Eleanor V Kane; John J Spinelli; Jennifer L Kelly; Carlo La Vecchia; Luigino Dal Maso; Marc Maynadié; Marshall E Kadin; Pierluigi Cocco; Adele Seniori Costantini; Christina A Clarke; Eve Roman; Lucia Miligi; Joanne S Colt; Sonja I Berndt; Andrea Mannetje; Anneclaire J de Roos; Anne Kricker; Alexandra Nieters; Silvia Franceschi; Mads Melbye; Paolo Boffetta; Jacqueline Clavel; Martha S Linet; Dennis D Weisenburger; Susan L Slager
Journal:  J Natl Cancer Inst Monogr       Date:  2014-08

10.  Common community-acquired infections and subsequent risk of multiple myeloma: a population-based study.

Authors:  Charlene M McShane; Liam J Murray; Eric A Engels; Ola Landgren; Lesley A Anderson
Journal:  Int J Cancer       Date:  2013-10-12       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.